Description and Appraisal of Outcome Measures - Clinical Review Report: Eculizumab (Soliris) - NCBI Bookshelf

Description and Appraisal of Outcome Measures - Clinical Review Report: Eculizumab (Soliris) - NCBI Bookshelf

To describe the following outcome measures and review their measurement properties (validity, reliability, responsiveness to change, and MID): Myasthenia Gravis Activities of Daily Living scale (MG-ADL)Quantitative Myasthenia Gravis (QMG) scoreMyasthenia Gravis Composite (MGC) scoreMyasthenia Gravis Quality of Life 15-item scale (MG-QoL15)Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS)Quality of Life in Neurological Disorders Fatigue Scale (Neuro-QoL Fatigue)European Quality of Life (EuroQol) Health 5-Dimensions (EQ-5D) questionnaire.

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Myasthenia Gravis: Case Study - Physiopedia

Full article: A US cost-minimization model comparing ravulizumab

Full article: A US cost-minimization model comparing ravulizumab

Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome

Full article: Quantifying the economic effects of ravulizumab

Brain Sciences, Free Full-Text

Clinical Evidence - Clinical Review Report: Eculizumab (Soliris

Clinical Review Report: Eculizumab (Soliris) - NCBI Bookshelf